Antithymocyte immunoglobulin (rabbit)
- Generic Name
- Antithymocyte immunoglobulin (rabbit)
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-60-9
- Unique Ingredient Identifier
- D7RD81HE4W
- Background
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
- Indication
For prevention of renal transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
- Conditions
- Interventions
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01490723
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2011-11-15
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 256
- Registration Number
- NCT01471444
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT01471067
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
- Conditions
- Interventions
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 44
- Registration Number
- NCT01445821
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Everett Meyer
- Target Recruit Count
- 44
- Registration Number
- NCT01392989
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Hospital do Rim e Hipertensão
- Target Recruit Count
- 300
- Registration Number
- NCT01354301
- Locations
- 🇧🇷
Hospital do rim e Hipertensao, Sao Paulo, Brazil
Research Study of ATG and Rituximab in Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2018-11-29
- Target Recruit Count
- 10
- Registration Number
- NCT01318915
- Locations
- 🇺🇸
University of California San Francisco Medical Center, San Francisco, California, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Rogosin Institute/New York Presbyterian-Cornell, New York, New York, United States
Low Dose Thymoglobin in Renal Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Lahey Clinic
- Target Recruit Count
- 44
- Registration Number
- NCT01280617
- Locations
- 🇺🇸
Lahey Clinic, Burlington, Massachusetts, United States
A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT01279616
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols
- Conditions
- Interventions
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 200
- Registration Number
- NCT01172418
- Locations
- 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.